The Latest Cardiac and Vascular News
PHOENIX, Feb. 17, 2022 /PRNewswire/ — Dignity Health in Arizona is launching the first research study in North America in which genetic testing is used to identify men and women at risk of developing heart disease based on the makeup of their DNA. If proven effective in clinical trials, this form of genetic testing may be adopted globally to prevent […]
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients […]
REVERSE-HF will evaluate rehospitalizations and survival when using the Aquadex therapy MINNEAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will evaluate the clinical outcomes and economic value of its Aquadex® therapy in comparison to intravenous diuretics for the treatment of fluid overload in patients with worsening […]
These authorizations enable the simultaneous launch of recruitment for these international studies, which should be completed in the first half of 2023. The INSIGHT and INSIGHT 2 randomized, placebo-controlled studies are designed to include a total of 800 volunteers with mild to moderate elevated blood pressure, with 400 volunteers in […]
Findings from Cleerly’s groundbreaking CLARIFY 2 study echo the recent American College of Cardiology guidelines on the use of CCTA for non-invasive heart disease evaluation. The study, the second of six studies comparing Cleerly analysis against current gold standards to plaque and coronary artery imaging, demonstrates Cleerly’s effectiveness in the identification and exclusion of […]
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within the collaboration, Cytokinetics will provide funding and support for several initiatives […]
– Phase 1/2 clinical trial expected to initiate in mid-2022 – – LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate across its pipeline – NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a diverse […]
Cardiovascular disease (CVD), a leading cause of death and disability worldwide, involves structural and functional changes in the heart Local sterile inflammation by the innate immune system results in a signalling cascade, particularly activation of NLRP3 NLRP3 activation, along with processing and release of downstream associated pro-inflammatory cytokines, IL-1β and […]
WASHINGTON–(BUSINESS WIRE)–Heart Valve Voice US, a nonprofit patient advocacy organization, is launching a new mobile app for its popular My Valve My Voice patient community. The app, now available for iOS and Android users, is among several initiatives for American Heart Month and Valve Disease Day announced today by the organization. “The […]
CHICAGO, Feb. 15, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company building a physiological waveform AI platform to manage cardiac disease, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device status for its novel algorithm to identify patients at risk of decompensated heart failure. The algorithm analyzes […]
